新奇
发表于 2025-3-28 17:31:19
ESKD Complications: CKD-MBD, and phosphorus by altering the production of calcitriol, PTH, FGF-23, and klotho. Eventually these compensatory responses become unable to maintain normal mineral homeostasis, resulting in (1) altered serum concentrations of calcium, phosphorus, PTH, calcitriol, FGF-23, and klotho, (2) disturbances
calumniate
发表于 2025-3-28 21:30:50
Peritoneal Dialysis in Diabetic Patients, new-onset diabetes. For those with pre-existing diabetes, worsening of diabetic control seems uncommon, unless the patient needs hypertonic cycles. Non-glucose-based PD solution may make diabetic control easier in some patients.
贝雷帽
发表于 2025-3-29 01:30:33
http://reply.papertrans.cn/17/1601/160029/160029_43.png
ABOUT
发表于 2025-3-29 04:50:18
http://reply.papertrans.cn/17/1601/160029/160029_44.png
防水
发表于 2025-3-29 08:15:00
http://reply.papertrans.cn/17/1601/160029/160029_45.png
OASIS
发表于 2025-3-29 14:31:42
Entzinkung von Gichtstaub im Schmelzzyklonxia-inducible factor-prolyl hydroxylase inhibitors). Finally factors unique to PD are discussed to crystalize the unique challenges and opportunities inherent in treating ESKD-associated anemia in PD patients.
采纳
发表于 2025-3-29 18:03:46
History of Peritoneal Dialysis,p an appreciation for the amount of research, innovation, and perseverance that lead to the current status of PD. This chapter will outline the history of PD and review a number of major scientific breakthroughs that have collectively shaped how PD is currently practiced.
民间传说
发表于 2025-3-29 20:38:26
The Evolution of Peritoneal Dialysis Solutions,lysate. The durability of PD as a dialysis modality depends on the type of solution utilized and its long-term effects on the peritoneal membrane. Many have argued that biocompatible solutions are ideal because they are proposed to limit the long-term degradation of the peritoneal membrane.
MOT
发表于 2025-3-30 01:05:40
http://reply.papertrans.cn/17/1601/160029/160029_49.png
团结
发表于 2025-3-30 07:54:22
Anemia Management in Peritoneal Dialysis,xia-inducible factor-prolyl hydroxylase inhibitors). Finally factors unique to PD are discussed to crystalize the unique challenges and opportunities inherent in treating ESKD-associated anemia in PD patients.